Details for Patent: 9,242,986

Which drugs does patent 9,242,986 protect, and when does it expire?

Patent 9,242,986 protects TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ, and is included in six NDAs.

Protection for TIVICAY PD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in fourteen countries.

Summary for Patent: 9,242,986

Title:	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Abstract:	A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##
Inventor(s):	Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP)
Assignee:	SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:	14/272,823
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,242,986
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,242,986

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	TIVICAY PD	dolutegravir sodium	TABLET, FOR SUSPENSION;ORAL	213983-001	Jun 12, 2020		RX	Yes	Yes					Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes					Y
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes					Y

International Family Members for US Patent 9,242,986

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009325128
Australia	2014277831
Brazil	PI0923217